Classify Toxicity Before the Next Dose Identify the affected organ system and assign severity using the applicable NCI CTCAE criteria; review symptoms, physical findings, laboratory abnormalities, and relevant diagnostic tests. Evaluate pulmonary, gastrointestinal, hepatic, endocrine, renal, dermatologic, cardiac, neurologic, and infusion-related toxicities. Exclude clinically plausible alternative causes, including infection, when appropriate, without delaying evaluation of potentially serious immune-mediated toxicity. Arrange immediate evaluation, treatment interruption, hospitalization, or specialist consultation for urgent or potentially life-threatening presentations. Apply organ-specific FDA Table 1 criteria rather than CTCAE grade alone: withhold for Grade 2 pneumonitis, Grade 2–3 colitis, and suspected SJS, TEN, or DRESS; permanently discontinue for Grade 2–4 myocarditis and confirmed SJS, TEN, or DRESS. For Grade 3–4 endocrinopathies, withhold until clinically stable or permanently discontinue according to severity. Route toxicity to the existing mild/manageable, treatment-interruption, or permanent-stop pathway as applicable; direct every FDA-mandated permanent-discontinuation event, including Grade 2 myocarditis, to the existing permanent-stop pathway.
-
Pneumonitis: G2 withhold; G3–4 permanently discontinue
Clinical assessment Identify symptoms: New cough, dyspnea, chest discomfort, hypoxemia, or increased oxygen requirements. Evaluate: Pulse oximetry, respiratory status, and chest CT. Compare with previous imaging. Exclude alternative causes: Infection, pulmonary embolism, tumor progression, radiation injury, or cardiac disease. Grade severity: Use CTCAE v5.0 and assess symptoms, oxygen requirements, and functional impairment. Select management: Grade 1 → evaluate and monitor; Grade 2 → withhold cosibelimab; Grade 3–4 → permanently discontinue. Urgent action: Respiratory distress, significant hypoxemia, or rapidly progressive symptoms require immediate evaluation and stabilization.
-
Grade 1 Pneumonitis: Manage Toxicity and Monitor
The cosibelimab label gives no specific Grade 1 modification rule; close monitoring and individualized interruption are supported mainly by general checkpoint-inhibitor guidance. Grade 1 Pneumonitis Management: Monitor; No Routine Corticosteroids No routine corticosteroid or antibiotic treatment for asymptomatic radiographic findings alone. Assess oxygen saturation and exclude infection, tumor progression, pulmonary embolism, and other causes. Consider withholding cosibelimab, particularly if radiographic findings progress. Reassess symptoms and oxygen saturation closely; repeat chest CT in approximately 3–4 weeks, sooner if deterioration occurs. New symptoms → manage as Grade 2. New oxygen requirement → urgent hospital evaluation. If withheld, consider resumption after radiographic improvement and clinical reassessment.
-
Grade 2 Pneumonitis: Withhold Cosibelimab and Manage Toxicity
Withholding for Grade 2 pneumonitis is an explicit cosibelimab label requirement. Grade 2 Pneumonitis Management: Withhold and Start Corticosteroids Withhold cosibelimab. Start immediate-release prednisone tablets, 1–2 mg/kg orally daily. Reassess within 48–72 hours. Obtain pulmonary consultation; consider bronchoscopy and infection-directed testing. Use antibiotics when infection remains clinically plausible. Once improved to Grade ≤1, taper prednisone over at least 4–6 weeks, guided by symptoms and imaging. Worsening or no improvement → hospital assessment and escalation, commonly methylprednisolone sodium succinate (Solu-Medrol), 1–2 mg/kg IV daily. Grade 3–4 pneumonitis requires permanent cosibelimab discontinuation. Steroid-refractory disease requires pulmonary/infectious-disease review and specialist-selected additional immunosuppression. RESTART ONLY AFTER A QUALIFYING TEMPORARY HOLD FDA rule: resume after recovery to Grade 0-1 following an appropriate corticosteroid taper. Permanent stop if no Grade 0-1 recovery within 12 weeks of starting steroids or prednisone-equivalent dose cannot reach ≤10 mg/day within 12 weeks.
-
Colitis: G2–3 withhold; G4 permanently discontinue
These are the exact label-based colitis modification thresholds; infectious evaluation and escalation for steroid-refractory disease are guideline supported.
-
Grade 1 Colitis: Assess and Provide Supportive Care
The label does not assign a Grade 1 hold rule; supportive management and close monitoring are based primarily on general immune-toxicity guidance. Grade 1 Diarrhea/Colitis Management: Supportive Care and Close Reassessment Asymptomatic Grade 1 colitis requires no routine medication. For mild diarrhea: oral fluids, electrolyte replacement, dietary adjustment, and review of other causes. For uncomplicated diarrhea only, after infection and clinically significant inflammatory colitis are excluded, consider loperamide (Imodium), 4 mg orally initially, then 2 mg after each loose stool; maximum 16 mg/day under clinician direction. Avoid antimotility treatment with blood, fever, significant abdominal pain, distension, ileus, or suspected inflammatory colitis. No routine systemic corticosteroids. Reassess within 24–48 hours; persistent or worsening symptoms require additional investigation and escalation. Cosibelimab may continue if clinically appropriate.
-
Grade 2-3 Colitis: Withhold and Manage Toxicity
The interruption rule is explicit in the label, with diagnostic and immunosuppressive management informed by ASCO guidance. Grade 2–3 Colitis Management: Withhold and Treat Inflammation Withhold cosibelimab. Send stool testing, including C. difficile; obtain gastroenterology input and endoscopic assessment when appropriate. Grade 2: Start prednisone, 1 mg/kg orally daily. Grade 3, dehydration, or inability to tolerate oral medication: Hospitalize; give Solu-Medrol, 1–2 mg/kg IV daily, with IV fluids and electrolyte replacement. If insufficient improvement after approximately 48–72 hours, or earlier for high-risk endoscopic findings, discuss: Infliximab (Remicade or an appropriate biosimilar), 5 mg/kg IV, with subsequent doses commonly at weeks 2 and 6; or Vedolizumab (Entyvio), 300 mg IV at weeks 0, 2, and 6. Screen for hepatitis B and tuberculosis before biologic therapy when feasible; assess infection, perforation, and contraindications. Do not give infliximab with uncontrolled infection or bowel perforation. After improvement to Grade ≤1, taper corticosteroids over 4–6 weeks. Grade 4 colitis requires permanent cosibelimab discontinuation. RESTART ONLY AFTER A QUALIFYING TEMPORARY HOLD FDA rule: resume after recovery to Grade 0-1 following an appropriate corticosteroid taper. Permanent stop if no Grade 0-1 recovery within 12 weeks of starting steroids or prednisone-equivalent dose cannot reach ≤10 mg/day within 12 weeks.
-
Hepatitis: Select Thresholds by Liver Tumor Involvement and Baseline AST/ALT
Cosibelimab has distinct standard and baseline-adjusted hepatic thresholds that must be selected according to liver involvement and pretreatment transaminases.
-
Apply Baseline-Adjusted Hepatitis Hold/Stop Thresholds (Baseline AST/ALT >1 to ≤3 × ULN, then >5 to ≤10 × ULN; OR baseline > 3 to ≤5 x ULN, then >8 to ≤10 x ULN)
Hepatitis: Apply Baseline-Adjusted Cosibelimab Hold/Stop Thresholds Applies with liver tumor involvement and elevated baseline AST or ALT. Withhold: Baseline >1–3× ULN rising to >5–10× ULN, or baseline >3–5× ULN rising to >8–10× ULN. Permanently discontinue: AST or ALT >10× ULN, or total bilirubin >3× ULN. Baseline values outside the specified ranges require individualized hepatology/oncology assessment. Evaluate alternative causes and apply the hepatitis medication regimen below. Liver tumor involvement changes cosibelimab thresholds; it does not automatically establish immune hepatitis or dictate a different steroid dose. Hepatitis medications For established immune hepatitis with moderate abnormalities: prednisone, 0.5–1 mg/kg orally daily, guided by symptoms, trajectory, and hepatology assessment. For severe or rapidly worsening hepatitis: Solu-Medrol, 1–2 mg/kg IV daily; hospitalize for impaired synthetic function, encephalopathy, or other evidence of liver failure. Check AST/ALT, bilirubin, alkaline phosphatase, and INR; monitor daily in severe disease. If worsening or without meaningful improvement after approximately 3 days, obtain hepatology review and consider mycophenolate mofetil (CellCept), 500–1,000 mg orally twice daily, with CBC and infection monitoring. Avoid infliximab for immune-mediated hepatitis. After improvement to Grade ≤1, taper corticosteroids over at least 4–6 weeks. RESTART ONLY AFTER A QUALIFYING TEMPORARY HOLD FDA rule: resume after recovery to Grade 0-1 following an appropriate corticosteroid taper. Permanent stop if no Grade 0-1 recovery within 12 weeks of starting steroids or prednisone-equivalent dose cannot reach ≤10 mg/day within 12 weeks.
-
Apply Standard Hepatitis Hold/Stop Thresholds (AST/ALT > 3 to ≤8 x ULN OR bilirubin >1.5 to ≤3 x ULN)
Hepatitis: Apply Standard Cosibelimab Hold/Stop Thresholds Applies without liver tumor involvement, or with liver tumor involvement when baseline AST and ALT are normal. Withhold: AST or ALT >3–8× ULN, or total bilirubin >1.5–3× ULN. Permanently discontinue: AST or ALT >8× ULN, or total bilirubin >3× ULN. Evaluate viral hepatitis, obstruction, other medications, tumor progression, and alternative causes before attributing abnormalities to immune hepatitis. Apply the hepatitis medication regimen below; steroid intensity depends on current severity, not simply whether the drug is withheld. Hepatitis medications For established immune hepatitis with moderate abnormalities: prednisone, 0.5–1 mg/kg orally daily, guided by symptoms, trajectory, and hepatology assessment. For severe or rapidly worsening hepatitis: Solu-Medrol, 1–2 mg/kg IV daily; hospitalize for impaired synthetic function, encephalopathy, or other evidence of liver failure. Check AST/ALT, bilirubin, alkaline phosphatase, and INR; monitor daily in severe disease. If worsening or without meaningful improvement after approximately 3 days, obtain hepatology review and consider mycophenolate mofetil (CellCept), 500–1,000 mg orally twice daily, with CBC and infection monitoring. Avoid infliximab for immune-mediated hepatitis. After improvement to Grade ≤1, taper corticosteroids over at least 4–6 weeks. RESTART ONLY AFTER A QUALIFYING TEMPORARY HOLD FDA rule: resume after recovery to Grade 0-1 following an appropriate corticosteroid taper. Permanent stop if no Grade 0-1 recovery within 12 weeks of starting steroids or prednisone-equivalent dose cannot reach ≤10 mg/day within 12 weeks.
-
Endocrine toxicity: Identify Syndrome and Clinical Stability
Endocrine management depends on the affected axis, symptoms, metabolic stability, and hormone replacement rather than laboratory grade alone.
-
Grade 1 Stable / Controlled Endocrine Toxicity: Treat Hormone Deficiency and Monitor
Stable endocrine toxicity can generally be managed with appropriate hormone replacement and continued monitoring rather than routine immunotherapy discontinuation. Stable/Controlled Endocrine Toxicity Management: Replace the Deficient Hormone Continue cosibelimab when clinically stable and the specific endocrinopathy permits. Overt primary hypothyroidism: Use levothyroxine (Synthroid). A healthy younger adult may require approximately 1–1.6 micrograms/kg orally daily; start lower in older adults or cardiac disease, commonly 25 micrograms daily, then titrate. Mild asymptomatic TSH elevation does not automatically require treatment. Adjust levothyroxine using TSH/free T4 after approximately 6 weeks; use free T4 rather than TSH for central hypothyroidism. ACTH deficiency/adrenal insufficiency: Hydrocortisone (Cortef), 15–25 mg orally daily in divided doses, e.g. 15 mg on waking and 5 mg early afternoon. Primary adrenal insufficiency with mineralocorticoid deficiency: Add fludrocortisone acetate, usually 0.05–0.1 mg orally daily, adjusted to blood pressure and electrolytes. Do not routinely use it for secondary adrenal insufficiency. Exclude or treat adrenal insufficiency before starting levothyroxine. Provide sick-day instructions and emergency steroid education.
-
Grade 2 Symptomatic Endocrine Toxicity: Withhold Until Improved
The label supports considering interruption for Grade 2 endocrinopathy depending on clinical severity; withholding should not be presented as mandatory in every case. Endocrinopathies: Apply clinical-stability, acute-symptom resolution, and hormone-replacement criteria as appropriate. Grade 2 Symptomatic Endocrine Toxicity Management: Withhold and Treat the Specific Syndrome Withhold cosibelimab until acute symptoms improve and the patient is clinically stable; obtain endocrinology input. Hypothyroidism: Start or adjust levothyroxine using the regimen above, after assessing adrenal function. Symptomatic adrenal insufficiency without crisis: Temporarily increase hydrocortisone to approximately 30–50 mg orally daily in divided doses, then return to physiologic replacement as symptoms resolve under endocrine guidance. Symptomatic destructive thyroiditis: Consider immediate-release propranolol, starting at 10 mg orally every 6 hours, titrated to heart rate, blood pressure, and symptoms. Avoid with significant bradycardia, heart block, bronchospasm, or suspected myasthenia. Antithyroid drugs are not routinely useful for destructive thyroiditis; confirmed Graves disease needs a separate regimen. Hypophysitis: Replace deficient hormones. High-dose immunosuppressive steroids are generally reserved for compressive symptoms, visual compromise, or severe refractory headache. New insulin-deficient diabetes: Urgent endocrinology assessment and ketone testing. Use basal–bolus insulin, e.g. insulin glargine U-100 (Lantus) plus insulin lispro U-100 (Humalog). A typical initial total daily dose is 0.2–0.6 units/kg/day, individualized, with approximately half basal and half divided with meals. Include glucose monitoring, correction dosing, and hypoglycemia education. Adrenal crisis: Emergency hospital care; hydrocortisone sodium succinate (Solu-Cortef), 100 mg IV/IM immediately, then 200 mg/24 hours IV or 50 mg IV every 6 hours, plus IV isotonic saline tailored to cardiac/renal status. DKA: Hospital protocol with fluids, potassium, and regular human insulin U-100 (Humulin R), commonly 0.1 units/kg/hour IV. Delay insulin if potassium is <3.5 mmol/L until corrected; add dextrose and adjust insulin as glucose falls. Do not treat immune-mediated diabetes with high-dose steroids. Resume only after syndrome-specific stabilization and acute-symptom resolution.
-
Nephritis: Grade Creatinine Rise and Exclude Other Causes
The label bases modification on the CTCAE grade of creatinine elevation and requires alternative etiologies to be considered.
-
Grade 1 Nephritis: Evaluate and Monitor Renal Function
The label does not assign a specific Grade 1 nephritis modification, so evaluation and close monitoring are supported chiefly by general immune-toxicity guidance. Grade 1 Creatinine Rise: Evaluate and Monitor No routine corticosteroids for an isolated mild creatinine elevation. Assess hydration, urinalysis, electrolytes, obstruction, infection, contrast exposure, and other medications. Correct volume depletion cautiously; stop avoidable nephrotoxins and review potential interstitial-nephritis triggers, including NSAIDs and proton-pump inhibitors. Repeat creatinine promptly, with frequency guided by the trajectory. Consider a temporary cosibelimab hold while evaluating unexplained or progressive kidney injury. Escalate for rising creatinine, oliguria, significant proteinuria, or active urinary sediment.
-
Grade 2–3 Nephritis: Withhold Cosibelimab and Manage Nephritis
Withholding for Grade 2-3 creatinine elevation with immune-mediated nephritis is explicitly required by the label. Grade 2–3 Immune Nephritis: Withhold and Start Corticosteroids Withhold cosibelimab and obtain nephrology input; exclude other causes and consider kidney biopsy. Grade 2: Prednisone, 0.5–1 mg/kg orally daily, adjusted to severity and response. Grade 3 or rapidly worsening injury: Hospitalize; Solu-Medrol, 1–2 mg/kg IV daily, transitioning to oral prednisone when improving. Monitor creatinine, electrolytes, urine output, and fluid balance closely. Lack of improvement within 48–72 hours requires reassessment and specialist-directed escalation. Once improved to Grade ≤1, taper corticosteroids over at least 4–6 weeks. Cosibelimab-specific rules permit withholding for Grade 3 creatinine elevation; Grade 4 requires permanent discontinuation. RESTART ONLY AFTER A QUALIFYING TEMPORARY HOLD FDA rule: resume after recovery to Grade 0-1 following an appropriate corticosteroid taper. Permanent stop if no Grade 0-1 recovery within 12 weeks of starting steroids or prednisone-equivalent dose cannot reach ≤10 mg/day within 12 weeks.
-
Skin Toxicity: Grade Rash and Identify Serious Cutaneous Reactions
The label distinguishes mild nonbullous rash from suspected or confirmed SJS, TEN, and DRESS and assigns different treatment modifications.
-
Grade 1–2 Rash: Nonbullous, No Red Flags => Treat Rash and Monitor
The label states that emollients and topical corticosteroids may adequately manage mild to moderate nonbullous or nonexfoliative rash. Grade 1–2 Nonbullous Rash: Topical Treatment and Monitoring Apply a fragrance-free emollient at least twice daily. Trunk/limbs: Triamcinolone acetonide 0.1% cream, thin layer twice daily, initially for 1–2 weeks, then reassess. Face/folds: Use a low-potency product, e.g. hydrocortisone 1% cream, thin layer once or twice daily for up to 7 days, then reassess. Itch: Cetirizine (Zyrtec), 10 mg orally daily, with renal/age adjustment when indicated. Grade 1 generally permits continued cosibelimab. Persistent or function-limiting Grade 2 warrants dermatology review, consideration of a hold, and sometimes prednisone, 0.5–1 mg/kg orally daily, followed by a response-guided taper. Blistering, skin pain, mucosal lesions, fever, or facial swelling → urgent severe-reaction pathway.
-
Grade 3 Rash / Suspected Severe Reaction => Withhold and Evaluate Urgently
General Grade 3 toxicity usually warrants interruption, and suspected SJS, TEN, or DRESS is a specific label-defined withholding event requiring urgent evaluation. Suspected SJS / TEN / DRESS - withhold. Confirmed SJS / TEN / DRESS - permanently discontinue. Grade 3 Rash or Suspected Severe Cutaneous Reaction: Withhold and Urgently Assess Withhold cosibelimab; obtain urgent dermatology assessment and consider biopsy. Grade 3 inflammatory rash without SJS/TEN/DRESS: Prednisone, approximately 1 mg/kg orally daily, or Solu-Medrol, 1–2 mg/kg IV daily for severe disease or inability to take oral therapy. Continue appropriate topical treatment; taper systemic steroids over at least 4–6 weeks after improvement. Suspected SJS/TEN/DRESS: Urgent hospital assessment; withdraw other potential culprit drugs. Provide wound/mucosal care, fluid/electrolyte management, and ophthalmology assessment when indicated. Systemic treatment must match the confirmed syndrome. Severe DRESS with organ involvement commonly requires systemic corticosteroids; SJS/TEN may require a burn/ICU setting and specialist-selected immunomodulation. Do not assign one automatic steroid or IVIG regimen to every severe skin reaction. Confirmed SJS/TEN/DRESS → permanently discontinue cosibelimab. Otherwise, consider restart only after appropriate recovery and taper.
-
Suspected Myocarditis or Overlap Syndrome => Withhold and Urgently Investigate
Suspected myocarditis requires immediate interruption and urgent cardiac evaluation; confirmed Grade 2-4 myocarditis requires permanent discontinuation. The label also recognizes myocarditis-myositis-myasthenia overlap. Suspected Myocarditis/Myositis/Myasthenia Overlap: Withhold and Hospitalize Withhold cosibelimab; arrange emergency hospital assessment, continuous ECG monitoring, and cardiology/neurology consultation. Obtain ECG, serial troponin, CK, electrolytes, echocardiography, and respiratory-muscle assessment; investigate overlap even when one syndrome predominates. When immune myocarditis is considered likely, promptly start Solu-Medrol, 500–1,000 mg IV daily for 3 days, with immediate specialist review of response and subsequent dosing. After improvement, transition to prednisone, approximately 1 mg/kg orally daily, with a specialist-directed taper guided by troponin, rhythm, ventricular function, and symptoms. Persistent instability or inadequate response within 24–48 hours requires specialist-selected additional immunosuppression. There is no single established rescue regimen appropriate for every patient. Myasthenic involvement may require IVIG/plasma exchange and ventilatory support; corticosteroids alone may be insufficient. Confirmed Grade 2–4 myocarditis → permanently discontinue cosibelimab.
-
Neurologic Toxicity: G2 Withhold; G3–4 Permanently Discontinue
These modification thresholds are explicitly specified in the cosibelimab label; syndrome-specific evaluation is supported by ASCO.
-
Grade 1 Neurologic Toxicity: Evaluate and Monitor
Mild neurologic symptoms still require careful assessment because some neurologic syndromes can progress rapidly; the label has no universal Grade 1 modification rule. Grade 1 Neurologic Symptoms: Establish the Syndrome Before Treating Arrange neurologic assessment and investigate metabolic, nutritional, infectious, medication-related, and malignant causes. For mild isolated sensory neuropathy, no routine corticosteroids. Have a low threshold to withhold cosibelimab during evaluation. Neuropathic pain: Consider gabapentin (Neurontin), 100–300 mg orally at bedtime, titrating cautiously toward 300 mg three times daily if needed and tolerated. Adjust for kidney function and sedation. New weakness, ptosis, diplopia, dysphagia, respiratory symptoms, confusion, or autonomic instability → urgent hospital evaluation rather than routine Grade 1 management.
-
Grade 2 Neurologic Toxicity: Withhold Cosibelimab
The cosibelimab label explicitly requires withholding for Grade 2 neurologic toxicity. Grade 2 Neurologic Toxicity: Withhold; Treat by Syndrome Withhold cosibelimab and obtain urgent neurology input. Non-Guillain–Barré inflammatory peripheral neuropathy: Consider prednisone, 0.5–1 mg/kg orally daily, with response-guided taper and neuropathic-pain treatment as needed. Myasthenia: Hospital assessment, respiratory monitoring, and evaluation for myocarditis/myositis overlap. Pyridostigmine (Mestinon), 30 mg orally three times daily, titrated by neurology; corticosteroids and IVIG/plasma exchange may also be needed. Steroids can initially worsen weakness and require monitored specialist initiation. Encephalitis or Guillain–Barré syndrome: Route immediately to inpatient syndrome-specific care; these should not remain in a generic Grade 2 outpatient pathway. Specialist regimens may include Solu-Medrol, 1,000 mg IV daily for 3–5 days, plus IVIG or plasma exchange. When IVIG is selected, a common regimen is 2 g/kg total over 5 days, e.g. immune globulin IV (Gamunex-C), 0.4 g/kg/day for 5 days, using product-specific infusion precautions. Restart requires neurology approval and syndrome-specific eligibility; some diagnoses preclude rechallenge even when the initial grade appears low. RESTART ONLY AFTER A QUALIFYING TEMPORARY HOLD FDA rule: resume after recovery to Grade 0-1 following an appropriate corticosteroid taper. Permanent stop if no Grade 0-1 recovery within 12 weeks of starting steroids or prednisone-equivalent dose cannot reach ≤10 mg/day within 12 weeks.
-
Infusion Reaction: G1–2 Interrupt/Slow; G3–4 Permanently Stop
The infusion-reaction actions and selective premedication recommendation are explicitly label defined.
-
Grade 1–2 Infusion Reaction: Interrupt or Slow infusion
This is an exact label-based administration modification. Infusion reactions: Follow infusion-specific management. Grade 1–2 Infusion Reaction: Interrupt/Slow and Treat Symptoms Interrupt or slow the infusion; assess airway, breathing, circulation, oxygen saturation, and vital signs. Select medication according to symptoms: Itching/urticaria: Diphenhydramine, 25–50 mg IV once, given slowly; a less-sedating oral antihistamine may suit mild reactions. Fever/chills: Acetaminophen (Tylenol), 650 mg orally once, if appropriate. Persistent reaction: Consider Solu-Cortef, 100 mg IV once. Bronchospasm: Albuterol, 2.5–5 mg by nebulizer, with reassessment. These medications are options, not a mandatory combination. Resume only after symptoms resolve and the clinician approves, at a reduced rate under the institution’s infusion-reaction protocol. Suspected anaphylaxis: Activate emergency care and give epinephrine 1 mg/mL solution, 0.5 mg IM into the lateral thigh, repeating every 5 minutes as indicated under the emergency protocol. Antihistamines and steroids do not replace epinephrine. Grade 3–4 infusion reactions → permanently discontinue cosibelimab.